Free Alerts   Login
Health Care › Laboratory Analytical Instruments

BRKR Stock Price Correlated With Bruker Financials

BRKR Stock Price vs. Quarterly
BRKR
Income Statement
Cash Flow
Balance Sheet

BRKR Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

BRKR Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

BRKR Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
T. Rowe Price Investment Management.
13,192,344 sh
-1,499,560 sh
-10%
$969
-$189
Vanguard Group
9,896,786 sh
-434,358 sh
-4%
$727,215
$83,585
Blackrock.
9,823,445 sh
-361,964 sh
-4%
$721,826
$87,277
FMR
9,432,290 sh
-577,081 sh
-6%
$693,085
$69,502
Pallas Capital Advisors
8,425,357 sh
-1,055,087 sh
-11%
$619,095
$98,524
Massachusetts Financial Services /Ma/
8,080,071 sh
239,336 sh
3%
$593,723
$105,245
Rtw Investments, Lp
3,344,095 sh
-37,608 sh
-1%
$245,724
$35,044
State Street
3,157,361 sh
59,042 sh
2%
$232,003
$38,978
Alliancebernstein
2,417,380 sh
62,860 sh
3%
$177,629
$30,942
Invesco.
1,984,490 sh
34,345 sh
2%
$145,821
$24,328
Fuller & Thaler Asset Management.
1,888,350 sh
-345,253 sh
-15%
$138,756
-$397
Goldman Sachs Group
1,783,621 sh
-157,081 sh
-8%
$131,061
$10,155
Td Asset Management
1,664,779 sh
562,684 sh
51%
$122,328
$53,667
Geode Capital Management
1,643,100 sh
-142,843 sh
-8%
$120,752
$9,472
Brown Advisory
1,590,151 sh
35,873 sh
2%
$116,844
$20,013
Citadel Advisors
1,567,442 sh
1,560,442 sh
22292%
$115,176
$114,740
Millennium Management
1,417,204 sh
469,808 sh
50%
$104,136
$45,113
Price T Rowe Associates /Md/
1,373,548 sh
-355,844 sh
-21%
$100
-$8
Dimensional Fund Advisors
1,170,777 sh
-21,409 sh
-2%
$86,031
$11,756
Norges Bank
1,014,991 sh
1,014,991 sh
NEW
$74,582
$74,582
COMPANY PROFILE
1. Description of Business and Basis of Presentation

Bruker Corporation and its wholly-owned subsidiaries (“Bruker” or the “Company”) is a designer and manufacturer of proprietary life science and materials research systems and associated products that address the rapidly evolving needs of a diverse array of customers in life science, pharmaceutical, biotechnology, clinical and molecular diagnostics research, as well as in materials and chemical analysis in various industries and government applications. The Company’s core technology platforms include X-ray technologies, magnetic resonance technologies, mass spectrometry technologies, optical emission spectroscopy and infrared and Raman molecular spectroscopy technologies. The Company also manufactures and distributes a broad range of field analytical systems for chemical, biological, radiological, nuclear and explosives, or CBRNE, detection. The Company also develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and “big science” research. The Company maintains major technical and manufacturing centers in Europe, North America and Japan, and has sales offices located throughout the world. The Company’s diverse customer base includes life science, pharmaceutical, biotechnology and molecular diagnostic research companies, academic institutions, advanced materials and semiconductor manufacturers and government agencies.

Management reports results on the basis of the following two segments:

· Scientific Instruments. The operations of this segment include the design, manufacture and distribution of advanced instrumentation and automated solutions based on magnetic resonance technology, mass spectrometry technology, gas chromatography technology, X-ray technology, spark-optical emission spectroscopy technology, atomic force microscopy technology, stylus and optical metrology technology, and infrared and Raman molecular spectroscopy technology. Typical customers of the Scientific Instruments segment include: pharmaceutical, biotechnology and molecular diagnostic companies; academic institutions, medical schools and other non-profit organizations; clinical microbiology laboratories; government departments and agencies; nanotechnology, semiconductor, chemical, cement, metals and petroleum companies; and food, beverage and agricultural analysis companies and laboratories.

· Energy & Supercon Technologies. The operations of this segment include the design, manufacture and marketing of superconducting materials, primarily metallic low temperature superconductors, for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications, and ceramic high temperature superconductors primarily for fusion energy research applications. Typical customers of the Energy & Supercon Technologies segment include companies in the medical industry, private and public research and development laboratories in the fields of fundamental and applied sciences and energy research and academic institutions and government agencies. The Energy & Supercon Technologies segment is also developing superconductors and superconducting-enabled devices for applications in power and energy, as well as industrial processing industries.

The Company has announced plans to sell a minority ownership position in its Bruker Energy & Supercon Technologies, Inc. (“BEST”) subsidiary through an initial public offering of the capital stock of BEST. The Company believes the offering will provide Bruker shareholders greater visibility into BEST’s performance and growth and strengthen BEST’s access to financing for its revenue growth initiatives, including the development of products for the renewable energy and energy infrastructure markets.

The financial statements represent the consolidated accounts of the Company.  All significant intercompany accounts and transactions have been eliminated i

Free historical financial statements for Bruker Corp. See how revenue, income, cash flow, and balance sheet financials have changed over 52 quarters since 2011. Compare with BRKR stock chart to see long term trends.

Data imported from Bruker Corp SEC filings. Check original filings before making any investment decision.